Ignite Creation Date:
2024-05-05 @ 12:08 PM
Last Modification Date:
2024-10-26 @ 9:20 AM
Study NCT ID:
NCT00251186
Status:
TERMINATED
Last Update Posted:
2010-01-26
First Post:
2005-11-07
Brief Title:
First-Line Capecitabine and Cetuximab for Metastatic Colorectal Ca in Elderly Patients
Sponsor:
University of Medicine and Dentistry of New Jersey
Organization:
Rutgers The State University of New Jersey
Study Overview
Official Title:
Phase II Study of First-Line Capecitabine and Cetuximab for Treatment of Metastatic Colorectal Cancer in Elderly Patients andor Those With Multiple Comorbidities Unable to Receive Chemotherapy Doublets
Status:
TERMINATED
Status Verified Date:
2010-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Funding unavailable
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a Phase II clinical trial measuring the effectiveness of the combination of Capecitabine and cetuximab for first line treatment of colorectal cancer in elderly patients andor those with multiple comorbidities unable to receive standard chemotherapy This study will be open approximately 2-3 years Approximately 36 patients will be enrolled on this study The study will begin enrolling at The Cancer Institute of New Jersey with 17 patients in the first group If more than 4 responses are noted the accrual will continue to 36 patients throughout CINJOG
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| CINJ 070502 | None | None | None |